Results 221 to 230 of about 2,816 (233)

Lutetium-177-PSMA-imaging-and-therapy

Reactions Weekly
openaire   +2 more sources

Lutetium-177-PSMA imaging and therapy

Reactions Weekly, 2018
openaire   +1 more source

Lutetium Lu 177 Dotatate Approved by FDA

Cancer Discovery, 2018
exaly  

Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study

European Urology Oncology
Silke Gillessen, Boris Hadaschik, Alice Bernard-Tessier   +2 more
exaly  

Lutetium-177-PSMA-therapy/225-actinium-PSMA

Reactions Weekly, 2019
openaire   +1 more source

Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer

Journal of Clinical Medicine
Bala Basak Oven, Kaan Akçay, Oguzcan Kinikoglu   +2 more
exaly  

Development of polyethylene glycol-modified gold nanoparticles for the delivery of Lutetium-177- radiopharmaceuticals based on antibodies

Journal of Drug Delivery Science and Technology
Maskur -, Hendris Wongso, Humani, TS
exaly  

Samarium-153 and Lutetium-177 Chelation Properties of Selected Macrocyclic and Acyclic Ligands

Nuclear Medicine and Biology, 1998
exaly  

The real‐world outcomes of Lutetium‐177 PSMA‐617 radioligand therapy in metastatic castration‐resistant prostate cancer: Turkish Oncology Group multicenter study

International Journal of Cancer
Elvina Almuradova, Mustafa Seyyar, İvo Gökmen   +2 more
exaly  

Comparative Study of the Effect of Radiation Delivered by Lutetium-177 or Actinium-225 on Anti-GD2 Chimeric Antigen Receptor T Cell Viability and Functions

Cancers
Quaovi H Sodji, Matthew H Forsberg, Caroline Kerr   +2 more
exaly